Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

for all subjects continuing in the extension study and the average annual rate of change in eGFR in subjects identified as responders to migalastat HCl, excluding hyperfiltrators, was +1.6 mL/min/1.73m2.  Additionally, reduced 24-hour urine protein continues to be observed in multiple subjects identified as responders to migalastat HCl, with a mean 21% and median 34% reduction from baseline in this group of subjects.

Co-administration with ERT in Fabry Disease and Pompe DiseaseAmicus previously reported promising preclinical data demonstrating that the co-administration of a pharmacological chaperone with ERT has the potential to address key limitations of ERT. The addition of a pharmacological chaperone has been shown to prevent the loss of activity of ERT in the circulation, increase tissue uptake, and increase substrate reduction in multiple disease-relevant tissues. Preclinical proof of concept has been established for Fabry disease and Pompe disease.

The Company will present a review of new and historical data from preclinical studies of migalastat HCl co-administered with ERT in an animal model of Fabry disease.  Amicus and its partner GlaxoSmithKline PLC (GSK) are sponsoring an ongoing Phase 2 study evaluating the co-administration of migalastat HCl with ERT for Fabry disease.  Results from this study are expected in the second half of 2011.

In addition, Amicus will present pharmacokinetics and muscle distribution data from a Phase 1 study of AT2220 that support the planned Phase 2 clinical study of AT2220 co-administered with ERT in Pompe patients.  The Company expects to initiate this study in the first half of 2011 and to report preliminary results in the second half of 2011. The Company intends to seek U.S. FDA approval to lift the current hold on the AT2220 program as part of its development plan.

Diseases of NeurodegenerationAmicus is investigating the potential use of pharmacological chaperones f
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) announced today ... a poster presentation entitled "In Vivo Efficacy ... in,Nude Mice Bearing Human Melanoma Xenografts" at ... Cancer Therapeutics. SAIC-Frederick is,the prime contractor to ...
... Biosystems,Inc. (OTC Bulletin Board: WGBS), a leading developer ... cell research systems,today announced that Alnoor Shivji, WaferGen,s ... presentation at the Seventh,Annual BIO Investor Forum. The ... Palace Hotel in San Francisco, WaferGen,s presentation ...
... Soliris(R) in U.S. and Europe, Reported Net Sales ... Quarter Shipments, Company Revises Revenue Guidance Upward and ... 2008, Pipeline Progress in Hematology, Oncology, Transplant, Neurology, ... (eculizumab) net product sales of $76.5 million in Q3,2008 ...
Cached Biology Technology:Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium 2Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium 3WaferGen to Present at the Seventh Annual BIO Investor Forum 2Alexion Reports Third Quarter 2008 Results 2Alexion Reports Third Quarter 2008 Results 3Alexion Reports Third Quarter 2008 Results 4Alexion Reports Third Quarter 2008 Results 5Alexion Reports Third Quarter 2008 Results 6Alexion Reports Third Quarter 2008 Results 7Alexion Reports Third Quarter 2008 Results 8Alexion Reports Third Quarter 2008 Results 9Alexion Reports Third Quarter 2008 Results 10Alexion Reports Third Quarter 2008 Results 11Alexion Reports Third Quarter 2008 Results 12Alexion Reports Third Quarter 2008 Results 13Alexion Reports Third Quarter 2008 Results 14
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a ... announced that its DigitalPersona ® Pro Enterprise ... have been deployed throughout First Bank branch locations ... South Carolina and Virginia. First Bank, ... Southern Pines, North Carolina , selected ...
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... REDMOND, Wash. , Nov. 20, 2014 ... access for the Internet of Things (IoT), today announced ... position of chief operating officer. Previously a strategic advisor ... marketing, finance, and operations. Mr. Traynor is based out ... . He reports to Chris Muench , ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... HERNDON, Va., Aug. 5, 2011 GTSI Corp. (NASDAQ: ... integrator for federal, state and local governments, announced today ... by the U.S. Army.  This contract will provide war ... of persons of interest in the field. The contract ...
... PARK, Md. -- New computer modeling work shows that by ... atmosphere to less than 40 percent higher than it is ... means of reducing emissions. This includes more nuclear and renewable ... that capture and store carbon dioxide, and even using forests ...
... dinosaurs that lived near the South Pole, sometimes in the ... similar to dinosaurs that lived everywhere on the planet, according ... surprising fact falsifies a 13-year-old study and may help explain ... million years, said Holly Woodward, MSU graduate student in the ...
Cached Biology News:GTSI Wins Department of Defense Contract to Provide Biometric Automated Toolset Systems for U.S. Army 2Human influence on the 21st century climate: 1 possible future for the atmosphere 2Human influence on the 21st century climate: 1 possible future for the atmosphere 3Human influence on the 21st century climate: 1 possible future for the atmosphere 4New Montana State research sheds light on South Pole dinosaurs 2New Montana State research sheds light on South Pole dinosaurs 3
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
NATIVE RAT OSTEOCALCIN...
Form: Ready to use Applications: ELISA...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Biology Products: